Skip to content

Cilostazol and Aspirin in Acute Ischemic Stroke Patients with Branch Atheromatous Disease (STOP-BAD)

Cilostazol and Aspirin for the Treatment of Branch Atheromatous Disease in Southern Han Chinese with Acute Ischemic Stroke: a Perspective Randomized Open-Label Blinded End-Point Parallel Controlled Clinical Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030555
Enrollment
Unknown
Registered
2020-03-07
Start date
2020-03-09
Completion date
Unknown
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular disease

Interventions

dual antiplatelet group:Cilostazol, Aspirin and standard therapy
mono antiplatelet group:Aspirin and standard therapy

Sponsors

Maoming People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) In accordance with the diagnostic criteria of ischemic stroke according to the Chinese Guidelines for Cerebrovascular Disease Prevention and Treatment in 2018, pure motor hemiplegia with NIHSS score 4-8; 2) Within 24 hours of stroke onset; 3) First or previous stroke patients with a history of ischemic stroke (mRS score 0-1); 4) Age 40-85 years old; 5) Brain CT excluded cerebral hemorrhage, or CTA excluded >50% of the large vascular stenosis or occlusion; 6) MRI conformed to the definition of BAD: the lenticulostriate arteries BAD: three or more consecutive axial MRI diffusion-weighted imaging (DWI) transverse slices in the white matter of the LSA territory (internal capsule and/or corona radiata)or unilateral infarcts extending to the basal surface of the pons in the PPA territory (ventral pons) 7) Patients or their guardians signed informed consents.

Exclusion criteria

Exclusion criteria: 1) Receiving atepase intravenous thrombolysis; 2) Cardiogenic embolism; 3) Head CTA or MRA excluded middle cerebral artery M1 or basilar artery with symptomatic intracranial artery stenosis more than 50%; 4) Patients with mental disorders or cognitive impairment who were unable to live independently; 5) Patients who refused to participate in the study; and 6) Other patients who were not suitable for study.

Design outcomes

Primary

MeasureTime frame
Early neurological deterioration within 7 days after stoke onset;

Secondary

MeasureTime frame
Neurological function prognosis 14 days after onset;Favorable neurological prognosis 28 days after onset;New clinical vascular events (stroke, myocardial infarction or vascular death) within 28 days after onset of disease;

Countries

China

Contacts

Public ContactHao Li

Department of Neurology, Maoming People's Hospital

185416656@qq.com+86 13580020456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026